AI-generated analysis. Always verify with the original filing.
Biofrontera Inc. reported record Q4 2025 revenues of $17.1 million, up 36% from $12.6 million in Q4 2024, with gross margins expanding to 82.4% from 58.0% and operating income of $4.6 million versus a $1.7 million loss prior year, driven by a strategic asset purchase from Biofrontera AG. Full year 2025 revenues rose 12% to $41.7 million with net loss narrowing to $10.5 million from $17.7 million.
Event Type
Disclosure
Mandatory
Variant
8-K
in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the
Financial Statements and Exhibits. 99.1 Press release dated March 19, 2026 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within th